IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Metrics to compare | IGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIGXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −7.1x | 0.0x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.0x | −0.4x | 0.0x | |
Price / LTM Sales | 0.0x | 1.8x | 0.0x | |
Upside (Analyst Target) | 0.0% | 94.3% | 0.0% | |
Fair Value Upside | Unlock | 13.0% | 0.0% | Unlock |